CYP2D6 and GSTM1 genotypes in a Polish population

European Journal of Clinical Pharmacology

Volumn 55, Issue 5, 1999, Pages 389-392

  Gawronska Szklarz, B ^a   Wojcicki M ^a   Kuprianowicz, A ^a   Kedzierska, K ^a   Kedzierski, M ^a   Gornik W ^a   Pawlik, A ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

CYP2D6; Genetic polymorphism; GSTM1

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ADULT; AGED; ARTICLE; DRUG METABOLISM; FEMALE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; POLAND; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLAND; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0032839303     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050645     Document Type: Article

References (31)

1. Agúndez JAG, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J (1994) Genetic basis for differences in debrisoquine polymorphism between a Spanish and other white population. Clin Pharmacol Ther 55: 412-417
2. Alexandrie AK, Sundberg MI, Seidegárd J, Tornling G, Rannug A (1994) Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host to age at factors in relation to age onset, gender and histological cancer types. Carcinogenesis 15: 1785-1790
3. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
4. Black SH, Wolf CR (1991) The role of glutathione-dependent enzymes in drug resistance. Pharmacol Ther 51: 139-154
5. Board PG (1981) Biochemical genetics of glutathione S-transferases in man. Am J Hum Genet 33: 36-43
6. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in an European population. DNA Cell Biol 10: 545-558
7. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, et al. (1996) The cytochrome P4502D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60: 522-534
8. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51: 12-17
9. Daly AK, Cholerton S, Gregory W, Idle JR (1993) Metabolic polymorphisms. Pharmacol Ther 157: 129-160
10. Evans WE, Relling MW, Rahman A, McLeod H, Scott E, Lin JS (1993) Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 91: 2150-2154
11. Gawroñska-Szklarz B, Serwatowski P, Grodzki T, Kêdzierski M, Kêdzierska K, Kuprianowicz A, Pawlik A, Wójcicki M, Wrzeœniewska J (1998) Polymorphisms of CYP2D6 and GSTM1 genes and susceptibility to lung cancer (in Polish). Probl Ter Monit 4: 158-164
12. Gonzales FJ (1992) Human cytochrome P450: Problems and prospects. Trends Pharmacol Sci 13: 346-352
13. Griese EU, Zanger UM, Breudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8: 15-26
14. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P (1991) A fast method for high-quality genomic DNA extraction from whole human blood. BioTechniques 11: 298-301
15. Hayashi SI, Watanabe J, Kawajiri K (1992) High susceptibility to lung cancer analyzed in trans of combined genotypes of 450IA1 and Mu-class glutathione S-transferse genes. Jpn J Cancer Res 83: 866-870
16. Hou SM, Lambert B, Hemminkit (1995) Relationship between hprt mutant frequency, aromatic DNA adducts and genotypes for GSTM1 and NAT2 in bus maintenance workers. Carcinogenesis 16: 1913-1917
17. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine J Biol Chem 265: 17209-17214
18. Kalow W (1991) Interethnic variation of drug metabolism. Trends Pharmacol Sci 12: 102-107
19. Kunicki PK, Sitkiewicz D, Pawlik A, Bielicka-Sulżyc W, Borowiecka E, Gawroñska-Szklarz B, Sterna R, et al. (1995) Debrisoquine hydroxylation in a Polish population. Eur J Clin Pharmacol 47: 503-505
20. Legrand-Andréoletti M, Stücker I, Marez D, Galais P, Cosme J, Sabbagh J, et al. (1998) Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics 8: 7-14
21. Mannervik B, Alin P, Guthenberg C, Jensson H, Tahir MK, Warholm M, Jornvall H (1985) Identification of three classes of cytosolic glutathione transferase common to several mammalian species: Correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 82: 7202-7206
22. Nakamura K, Goto F, Ray WA, McAlister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402-408
23. Orzechowska-Juzwenko K, Pawlik J, Niewiñski P, Milejski P, Dembowski J, Turek J, et al. (1994) Genetically determined sparteine oxidation polymorphism in a Polish population. Eur J Clin Pharmacol 46: 481-483
24. Seidegárd J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ (1990) Isoenzyme(s) of glutathione transferase (class) as a marker for susceptibility to lung cancer: A follow-up study. Carcinogenesis 11: 33-36
25. Smith C, Gough A, Leigh P, Summers B, Harding A, et al. (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339: 1375-1377
26. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E (1997) Relationship between plasma desipramine levels. CYP2D6 phenotype and clinical response to desipramine: A prospective study. Eur J Clin Pharmacol 51: 395-398
27. Strange RC, Matharoo B, Flauder GC, Jones P, Cotton W, Elder JB, Deakin M (1991) The human glutathione S-transferases: A case-control study of the incidence of the GSTM1-0 phenotype in patients with adenocarcinoma. Carcinogenesis 12: 25-28
28. Tefre T, Daly AK, Armstrong M, Leathart IBS, Idle JR, Brogger A, Borresen AL (1994) Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 4: 47-57
29. Yamada H, Dahl ML, Lannfelt L, Viitamen M, Winblad B, Sjöqvist F (1998) CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 54: 479-481
30. Zhong S, Howie AF, Ketlerer B, Taylor J, Hayes ID, Beckett GI, Wathen CG, Wolf CR, Spurr NK (1991) Glutathione S-tranferase mu locus: Use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12: 1533-1537
31. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK (1993) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14: 1821-1824